CACNG6 antibody - N-terminal region (ARP35414_T100)
- Known as:
- CACNG6 (anti-) - N-terminal region (ARP35414_T100)
- Catalog number:
- arp35414_t100
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- CACNG6 antibody - N-terminal region (ARP35414_T100)
Related genes to: CACNG6 antibody - N-terminal region (ARP35414_T100)
- Gene:
- CACNG6 NIH gene
- Name:
- calcium voltage-gated channel auxiliary subunit gamma 6
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 19q13.42
- Locus Type:
- gene with protein product
- Date approved:
- 2000-10-24
- Date modifiied:
- 2016-10-05
Related products to: CACNG6 antibody - N-terminal region (ARP35414_T100)
Related articles to: CACNG6 antibody - N-terminal region (ARP35414_T100)
- Pneumonia caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) has a high mortality rate and exhibits multiple drug resistance, making current antibacterial treatments of limited efficacy. To address the challenges of ineffective drug accumulation at the infection site and excessive inflammation leading to tissue damage, this study developed a cell-based nano-bionic drug delivery system (denoted as PT@M2, PLGA-TIG nanoparticles loaded into M2 macrophages). This system encapsulates poly(lactic-co-glycolic acid) (PLGA) loaded with tigecycline within M2-type macrophages, thereby achieving stable circulation, rapid release in acidic microenvironments, and targeted delivery to the lungs. In vitro experiments showed that PT@M2 significantly reduced the minimum inhibitory concentration of CRKP, disrupted bacterial membranes, and induced reactive oxygen species accumulation. In a mouse pneumonia model, PT@M2 effectively reduced bacterial colonies, alleviated inflammatory responses, and improved pulmonary histopathology. Wefurther confirmed that PT@M2 could inhibit calcium ion influx by downregulating CACNG6, thereby indirectly modulating the MAPK pathway. In summary, PT@M2 enhances antibacterial efficacy through a dual mechanism of "bactericidal action + immune microenvironment remodeling," providing a novel therapeutic strategy for the treatment of multidrug-resistant bacterial infections. - Source: PubMed
Publication date: 2026/03/10
Cheng WeijingWu LingLiao YuZhang TingruiHan XiujuanTai ZongguangZhu QuangangChen ZhongjianTian JingDing NanWang Zhuo - The management and prevention of childhood asthma remain significant challenges. Mendelian randomization (MR) has emerged as a valuable tool for identifying novel therapeutic targets. In response, we conducted a comprehensive, druggable genome-wide MR analysis to elucidate potential therapeutic targets for childhood asthma. Our study integrated genomic data concerning druggable targets, expression quantitative trait loci (eQTLs), and results from genome-wide association studies on childhood asthma. Employing the MR technique, we explored the putative causal links between genes that are targets for drugs and the development of childhood asthma. To validate these causal associations, we utilized reverse MR analyses along with colocalization techniques. Moreover, we performed enrichment analysis, mapped protein interaction networks, and executed drug prediction algorithms and molecular docking studies. These methodologies were applied to gain critical insights that could guide the development of more potent and precise therapeutic agents. We identified 35 druggable genes significantly associated with childhood asthma (including BLVRA, SLC9A3, LYZ, SRPK1, HOXA5, LYVE1, S100A9, ADORA1, RPL13, IL7R, SLFN11, SHMT1, CLN8, TOP1MT, LPAR5, RNASET2, ANK1, H6PD, DSP, CDC25B, VWF, ITK, CACNG6, ITGB7, S100A8, ADAM12, ST14, BMP6, HK2, SYK, ABCA1, ULK4, KBTBD2, SLCO4C1), with BLVRA showing promise as a target. Our research suggests that BLVRA may be a promising target for childhood asthma treatment, aiding in the prioritization of drug development for childhood asthma. - Source: PubMed
Bi JunjieLiu XueZhang JingjingZhao Liqun - Patients with colorectal cancer undergoing chemotherapy often experience significant pain and fatigue. Limitations in understanding the complex phenotypes and biological mechanisms of these symptoms hinder effective interventions. - Source: PubMed
Publication date: 2025/06/27
Wu WeiziLi AolanSingh VijenderSalner AndrewChen Ming-HuiJudge Michelle PCong XiaomeiXu Wanli - The treatment and prevention of diabetic retinopathy (DR) remain significant challenges. Mendelian randomization (MR) has been widely used to explore novel therapeutic targets. In this study, we conducted a systematic druggable genome-wide MR analysis to explore potential therapeutic targets for DR. - Source: PubMed
Publication date: 2025/04/29
Xie LongPeng Yu QinShen Xiang - An efficient promoter with specific transcriptional activity plays significant roles in the regulation of expression of exogenous genes. The efficient promoter specific to skeletal muscles can achieve high expression of exogenous genes in skeletal muscles. This is of great significance for the targeted improvement of livestock meat quality by combining gene editing and traditional breeding techniques. To identify efficient promoters specific to the skeletal muscles of buffalo, in the present study, a total of 14 genes, , , , , , , , , , , , , , and , were firstly screened as skeletal-muscle-specific expressed genes based on high-throughput sequencing data. Among them, only two genes - namely, and - were identified to be specifically and efficiently expressed in the skeletal muscles of buffalo by quantitative reverse transcription polymerase chain reaction (RT-qPCR). Then, the transcriptional activity of different truncated fragments of the upstream putative promoter region of and were evaluated by the dual luciferase reporter gene detection system in mouse C2C12 cells and buffalo skeletal muscle cells. As a result, both core promoters of and were identified to have specifically and efficiently transcriptional activity in skeletal muscle tissue while the transcriptional activity of the core promoters of was more efficient. These results provide significant information for the targeted improvement of meat quality in buffaloes and other livestock animals. - Source: PubMed
Publication date: 2025/01/31
Huang JiepingGuo DuoZhu RuiruiWang HaopengYang ChunyanShi DeshunShang Jianghua